FSH - an Aging Hormone?

FSH——一种衰老激素?

基本信息

项目摘要

PROGRAM SUMMARY Obesity and osteoporosis are global public health hazards that commonly affect older individuals and often co-exist in postmenopausal women. While a restricted armamentarium of therapies is available for osteoporosis, the five approved agents for obesity are limited by poor efficacy and unacceptable side effects. Hence, new approaches to treat these two chronic conditions of aging require a collaborative and rigorous integrative program between independent, but fully interactive laboratories. This U19 builds on a firm foundation of rigorous and transparent research, born from a longstanding collaboration between Drs. Mone Zaidi and Clifford Rosen, the results of which were published last year (Nature, 2017, PMID: 28538730). We identified FSH as a unique target to prevent both obesity and osteoporosis. We raised a polyclonal antibody to Fshβ, which, by blocking its access to the Fsh receptor (Fshr), prevented high-fat-diet-induced obesity and ovariectomy-induced osteoporosis. In addition, our Fsh antibody triggered the appearance of energy- producing ‘beige’ adipocytes in white adipose tissue. Based on these studies and others, we now postulate that FSH may also be a critical aging hormone. We therefore propose to undertake a comprehensive, multipronged and interdisciplinary study of the effects of blocking Fsh signaling, either pharmacologically using our monoclonal anti-Fsh antibodies or genetically in Fshr-/- mice, on lifespan, fat gain, bone marrow adiposity, and skeletal health in mice. We will also study the mechanism of Fsh action on fat cells using ThermoMice that report ‘beiging,’ AdipoChaser mice that measure de novo adipogenesis, and state-of-the-art technologies for transcriptome, lipidome and bioenergetic profiling. To buttress our preclinical observations and, with a view of testing our monoclonal antibodies in people, we propose an epidemiological study of older women and men in the AGES-Reykjavik Cohort. We will examine whether serum FSH can be used as a surrogate marker for bone loss, visceral fat gain, bone marrow adiposity, and ultimately, fracture risk. To provide necessary resources across the four investigative sites–Icahn School of Medicine at Mount Sinai, Maine Medical Center Research Institute, University of Texas Southwestern Medical Center and the University of California at San Francisco–we propose three overarching multifunctional cores: a Skeletal and Metabolic Phenotyping Core, an Antibody Production and Testing Core, and an Administrative and Biostatistics Support Core. In sum, our U19 proposal should allow us to break new ground in our understanding of two prevalent disorders of aging, in addition to opening new avenues for therapeutic interventions for our increasing numbers of older adults.
计划摘要 肥胖和骨质疏松症是全球性的公共健康危害,通常影响老年人和 通常在绝经后妇女中并存。虽然有限的治疗手段可以用来治疗 骨质疏松症,五种被批准的肥胖剂,由于疗效差和不可接受的副作用而受到限制。 因此,治疗这两种慢性老龄化的新方法需要合作和严格的 独立但完全互动的实验室之间的综合计划。这款U19是在一家公司的基础上建造的 严格和透明的研究基础,诞生于Mone博士之间的长期合作 Zaidi和Clifford Rosen,其结果于去年发表(《自然》,2017年,PMID:28538730)。我们 确定促卵泡激素是预防肥胖和骨质疏松症的唯一目标。我们提出了一种多克隆抗体来 卵泡刺激素β,通过阻断其与卵泡刺激素受体的通路,防止高脂饮食诱导的肥胖和 卵巢切除引起的骨质疏松症。此外,我们的FSH抗体引发了能量的出现- 在白色脂肪组织中产生“米色”脂肪细胞。基于这些研究和其他研究,我们现在假设 FSH也可能是一种关键的衰老荷尔蒙。因此,我们建议进行一项全面的、 阻断FSH信号转导效应的多管齐下跨学科研究 我们的抗FSH单抗或在FSHR-/-小鼠中遗传,对寿命、脂肪增加、骨髓肥胖症、 和老鼠的骨骼健康。我们还将利用ThermoMice研究FSH对脂肪细胞的作用机制 这份报告称,AdipoChaser老鼠测量了新生脂肪生成,以及最先进的技术 用于转录组、脂组和生物能量分析。以支持我们的临床前观察,并着眼于 为了在人体中测试我们的单抗,我们建议对老年女性和男性进行流行病学研究 在时代中-雷克雅未克队列。我们将研究血清FSH是否可以作为替代标记物 骨质流失,内脏脂肪增加,骨髓肥胖症,最终导致骨折风险。以提供必要的 四个调查地点的资源-西奈山伊坎医学院、缅因州医疗中心 得克萨斯大学西南医学中心研究所和加州大学旧金山分校 我们提出了三个主要的多功能核心:骨骼和新陈代谢表型核心,以及 抗体生产和检测核心,以及行政和生物统计学支持核心。总而言之,我们的U19 该提案应该使我们在理解两种普遍存在的衰老障碍方面取得新的突破, 此外,还为越来越多的老年人开辟了治疗干预的新途径。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

CLIFFORD JAMES ROSEN其他文献

CLIFFORD JAMES ROSEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('CLIFFORD JAMES ROSEN', 18)}}的其他基金

Northern New England Clinical and Translational Research Network
新英格兰北部临床和转化研究网络
  • 批准号:
    10681809
  • 财政年份:
    2021
  • 资助金额:
    $ 229.85万
  • 项目类别:
Understanding Factors Influencing COVID-19 Testing and Vaccination in Immigrant Low-income and Homeless Populations and Testing Targeted Interventions
了解影响移民低收入和无家可归人群的 COVID-19 检测和疫苗接种的因素以及测试有针对性的干预措施
  • 批准号:
    10413438
  • 财政年份:
    2021
  • 资助金额:
    $ 229.85万
  • 项目类别:
FSH - an Aging Hormone?
FSH——一种衰老激素?
  • 批准号:
    10112794
  • 财政年份:
    2019
  • 资助金额:
    $ 229.85万
  • 项目类别:
FSH - an Aging Hormone?
FSH——一种衰老激素?
  • 批准号:
    10577830
  • 财政年份:
    2019
  • 资助金额:
    $ 229.85万
  • 项目类别:
Physiology Core
生理学核心
  • 批准号:
    10711694
  • 财政年份:
    2017
  • 资助金额:
    $ 229.85万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10891897
  • 财政年份:
    2017
  • 资助金额:
    $ 229.85万
  • 项目类别:
Northern New England Clinical and Translational Research Network
新英格兰北部临床和转化研究网络
  • 批准号:
    10675577
  • 财政年份:
    2017
  • 资助金额:
    $ 229.85万
  • 项目类别:
Northern New England Clinical and Translational Research Network-Equipment
新英格兰北部临床和转化研究网络设备
  • 批准号:
    10797663
  • 财政年份:
    2017
  • 资助金额:
    $ 229.85万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10871636
  • 财政年份:
    2017
  • 资助金额:
    $ 229.85万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10505150
  • 财政年份:
    2017
  • 资助金额:
    $ 229.85万
  • 项目类别:

相似海外基金

Deciphering the role of adipose tissue in common metabolic disease via adipose tissue proteomics
通过脂肪组织蛋白质组学解读脂肪组织在常见代谢疾病中的作用
  • 批准号:
    MR/Y013891/1
  • 财政年份:
    2024
  • 资助金额:
    $ 229.85万
  • 项目类别:
    Research Grant
ESTABLISHING THE ROLE OF ADIPOSE TISSUE INFLAMMATION IN THE REGULATION OF MUSCLE MASS IN OLDER PEOPLE
确定脂肪组织炎症在老年人肌肉质量调节中的作用
  • 批准号:
    BB/Y006542/1
  • 财政年份:
    2024
  • 资助金额:
    $ 229.85万
  • 项目类别:
    Research Grant
Activation of human brown adipose tissue using food ingredients that enhance the bioavailability of nitric oxide
使用增强一氧化氮生物利用度的食品成分激活人体棕色脂肪组织
  • 批准号:
    23H03323
  • 财政年份:
    2023
  • 资助金额:
    $ 229.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Development of new lung regeneration therapies by elucidating the lung regeneration mechanism of adipose tissue-derived stem cells
通过阐明脂肪组织干细胞的肺再生机制开发新的肺再生疗法
  • 批准号:
    23K08293
  • 财政年份:
    2023
  • 资助金额:
    $ 229.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Canadian Alliance of Healthy Hearts and Minds: Dissecting the Pathways Linking Ectopic Adipose Tissue to Cognitive Dysfunction
加拿大健康心灵联盟:剖析异位脂肪组织与认知功能障碍之间的联系途径
  • 批准号:
    479570
  • 财政年份:
    2023
  • 资助金额:
    $ 229.85万
  • 项目类别:
    Operating Grants
Determinants of Longitudinal Progression of Adipose Tissue Inflammation in Individuals at High-Risk for Type 2 Diabetes: Novel Insights from Metabolomic Profiling
2 型糖尿病高危个体脂肪组织炎症纵向进展的决定因素:代谢组学分析的新见解
  • 批准号:
    488898
  • 财政年份:
    2023
  • 资助金额:
    $ 229.85万
  • 项目类别:
    Operating Grants
A study on the role of brown adipose tissue in the development and maintenance of skeletal muscles
棕色脂肪组织在骨骼肌发育和维持中作用的研究
  • 批准号:
    23K19922
  • 财政年份:
    2023
  • 资助金额:
    $ 229.85万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
A mechanism of lipid accumulation in brown adipose tissue
棕色脂肪组织中脂质积累的机制
  • 批准号:
    10605981
  • 财政年份:
    2023
  • 资助金额:
    $ 229.85万
  • 项目类别:
Obesity and Childhood Asthma: The Role of Adipose Tissue
肥胖和儿童哮喘:脂肪组织的作用
  • 批准号:
    10813753
  • 财政年份:
    2023
  • 资助金额:
    $ 229.85万
  • 项目类别:
Estrogen Signaling in the Ventromedial Hypothalamus Modulates Adipose Tissue Metabolic Adaptation
下丘脑腹内侧区的雌激素信号调节脂肪组织代谢适应
  • 批准号:
    10604611
  • 财政年份:
    2023
  • 资助金额:
    $ 229.85万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了